Jonathan Miller
Stock Analyst at Evercore ISI
(0.70)
# 4,201
Out of 5,108 analysts
60
Total ratings
42.9%
Success rate
-4.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Reiterated: Buy | $10 | $5.15 | +94.17% | 3 | Oct 20, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $25 | $5.06 | +394.07% | 3 | Oct 15, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $48 → $44 | $30.94 | +42.21% | 4 | Sep 29, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $4 | $1.33 | +201.89% | 3 | Sep 1, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $76 | $51.78 | +46.79% | 3 | Aug 31, 2026 | |
| ARVN Arvinas | Rated: Buy | $19 → $14 | $7.42 | +88.68% | 4 | Aug 10, 2026 | |
| NTLA Intellia Therapeutics | Upgraded: Buy | $16 → $24 | $12.31 | +94.96% | 6 | Aug 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $23 | $12.28 | +87.30% | 5 | Jul 20, 2026 | |
| EDIT Editas Medicine | Reiterated: Buy | $15 | $2.72 | +451.47% | 3 | May 27, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $9 | $1.73 | +420.23% | 1 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $22 | $18.18 | +21.01% | 5 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $24 | $14.91 | +60.97% | 2 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $15 | $6.65 | +125.56% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 → $13 | $0.4444 | +2,825.29% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $19.31 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.59 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $4.46 | +34.53% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $10.65 | n/a | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.31 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.12 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.37 | n/a | 2 | May 5, 2021 |
Shattuck Labs
Oct 20, 2026
Reiterated: Buy
Price Target: $10
Current: $5.15
Upside: +94.17%
Entrada Therapeutics
Oct 15, 2026
Reiterated: Buy
Price Target: $25
Current: $5.06
Upside: +394.07%
Zymeworks
Sep 29, 2026
Reiterated: Buy
Price Target: $48 → $44
Current: $30.94
Upside: +42.21%
PMV Pharmaceuticals
Sep 1, 2026
Reiterated: Buy
Price Target: $4
Current: $1.33
Upside: +201.89%
CRISPR Therapeutics AG
Aug 31, 2026
Reiterated: Buy
Price Target: $76
Current: $51.78
Upside: +46.79%
Arvinas
Aug 10, 2026
Rated: Buy
Price Target: $19 → $14
Current: $7.42
Upside: +88.68%
Intellia Therapeutics
Aug 7, 2026
Upgraded: Buy
Price Target: $16 → $24
Current: $12.31
Upside: +94.96%
4D Molecular Therapeutics
Jul 20, 2026
Reiterated: Buy
Price Target: $23
Current: $12.28
Upside: +87.30%
Editas Medicine
May 27, 2026
Reiterated: Buy
Price Target: $15
Current: $2.72
Upside: +451.47%
Nkarta
May 18, 2026
Reiterated: Buy
Price Target: $9
Current: $1.73
Upside: +420.23%
May 11, 2026
Reiterated: Buy
Price Target: $23 → $22
Current: $18.18
Upside: +21.01%
Apr 28, 2026
Reiterated: Buy
Price Target: $11 → $24
Current: $14.91
Upside: +60.97%
Apr 13, 2026
Reiterated: Buy
Price Target: $13 → $15
Current: $6.65
Upside: +125.56%
Mar 9, 2026
Reiterated: Buy
Price Target: $1 → $13
Current: $0.4444
Upside: +2,825.29%
Mar 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $19.31
Upside: -
Jan 26, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.59
Upside: -
Nov 28, 2025
Reiterated: Buy
Price Target: $6
Current: $4.46
Upside: +34.53%
Sep 30, 2025
Reiterated: Buy
Price Target: $12
Current: $10.65
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: n/a
Current: $2.31
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.12
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $8.37
Upside: n/a